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“The way I see it, every life is a pile of good things and bad things. The good things 
don't always soften the bad things, but vice-versa, the bad things don't necessarily spoil 
the good things and make them unimportant.” 
--- The Doctor 
  
  
  
ABSTRACT 
The maintenance of immunological tolerance is vital for preventing the immune system to 
damage normal tissues and physiological function of the body.  CD4+FOXP3+ regulatory T 
(Treg) cells can suppress immune responses in a dominant manner and are essential for 
immunological tolerance. Although many pathways and molecules have been attributed to 
the suppressive function of Treg cells, the exact nature of the Treg cell-mediated suppression 
program is still elusive. 
In this thesis, I aimed to study the role of different protein isoforms, in particular FOXP3 and 
CTLA-4 isoforms, in the function of Treg cells and uncover the consequences of Treg cell-
mediated suppression on dendritic cells (DCs). 
In paper I the aim was to understand the regulation and functional consequences of FOXP3 
isoform expression in chronic inflammatory diseases in human. We found that FOXP3 
isoforms were differentially expressed in biopsies from IBD patients. Moreover, the pro-
inflammatory cytokine IL-1β promoted the exclusion of FOXP3 exon 7, which favoured the 
differentiation of naïve CD4+ T cells into Th17 cells. 
In paper II we generated a mouse model (Foxp3δ2δ7 mouse) where Treg cells exclusively 
express an FOXP3 isoform lacking both exon 2 and exon 7 (FOXP3δ2δ7). We found that 
FOXP3δ2δ7 was unable to confer suppressive function of Treg cells in vivo. Homozygote 
Foxp3δ2δ7 mice phenocopied Foxp3 deficient scrufy mice and died from severe autoimmune 
disorder starting from 3 weeks of age. The Foxp3δ2δ7 mouse may provide a useful alternative 
for studying FOXP3 isoform function in Treg cells in vivo. 
In paper III we investigated the role of CTLA-4 in Treg cell-mediated suppression on DCs. 
We generated a mouse model (Ctla4ex2fl/flFoxp3-Cre mouse) where Treg cells exclusively 
express an isoform of CTLA-4 that lacks the extracellular binding domain encoded by Ctla4 
exon 2. Ctla4ex2fl/flFoxp3-Cre mice were born healthy and only started to display 
inflammatory lesions in environmental surfaces such as the lung and intestine after 4 months 
of age. In vitro co-culture experiments demonstrated that Treg cells from Ctla4ex2fl/flFoxp3-
Cre mice were fully capable of inhibiting the up-regulation of CD80/CD86 on DCs. DCs co-
cultured with Ctla4ex2fl/flFoxp3-Cre Treg cells had decreased ability to support effector T cell 
proliferation. Unexpectedly, we also found that DCs up-regulated PD-L2 when co-cultured 
with wild type Treg cells in a CTLA-4 dependent manner. Collectively these data suggest 
that CTLA-4 mediated trans-endocytosis is a dispensable mechanism for Treg cell-mediated 
suppression and that Treg cell-mediated suppression on DCs is a multi-faceted process 
involving both CTLA-4 dependent and independent mechanisms. 
In summary, these studies showed that it is necessary to investigate FOXP3 and Treg cell 
function on an isoform basis, and that Treg cell-mediated suppression on DCs is a multi-
faceted program that involves both CTLA-4 dependent and independent mechanisms.   
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1 INTRODUCTION 
1.1 THE IMMUNE SYSTEM 
The immune system is a complex defence system with many biological structures and 
processes that protects an organism from infections and diseases. Generally speaking, the 
immune system can be divided into two subsystems: the innate immune system and adaptive 
immune system. The innate immune system appeared earlier in evolution, and can be found 
in all plants and animals. It provides a quick but non-specific response towards pathogens as 
a first line of defence. The adaptive immune system emerged later in evolution and can only 
be found in vertebrates, including both jawed and jawless vertebrates (Guo et al. 2009; 
Flajnik & Kasahara 2010). Compared to the innate immune system, the adaptive immune 
system has much higher specificity towards antigens, and it can also create immunological 
memory after an initial response. 
The innate immune system includes physical and chemical barriers as well as cellular innate 
immune responses. Physical and chemical barriers include epithelial layers of the skin, 
mucosal surfaces at various environmental surfaces, and soluble substances with 
antimicrobial activity or low PH value, etc. Cellular innate immune responses rely on 
phagocytes that can recognize conserved motifs found on the microbes and damage-
associated molecular patterns (DAMPs) due to aging, cell death or tissue damages. The 
receptors that can recognize DAMPs are called pattern recognition receptors (PRRs). There 
are 4 major families of PRRs, they are toll-like receptors (TLRs), c-type lectin receptors 
(CLRs), retinoic acid-inducible gene-I-like receptors (RLRs), and nod-like receptors and 
nucleotide oligomerization domain/leucine-rich repeat-containing receptors (NLRs). TLRs 
are the first family of PRRs to be discovered and are also the best-characterized PRRs. Today 
there are 10 functional TLRs identified in human and 12 in mouse. Among these TLRs, 
TLR1, TLR2, TLR4, TLR5, and TLR6 are localized on the cell surface and recognize 
microbial membrane components whereas TLR3, TLR7, TLR8, and TLR9 are localized in 
intracellular vesicles and recognize nucleic acids (Kawai & Akira 2011).  
The adaptive immune system has two major components: 1) T-lymphocytes (T cells), 
including both CD4+ T cells and CD8+ T cells, and 2) B-lymphocytes (B cells). After 
activation naïve CD4+ T cells can differentiate into many subsets of helper T (Th) cells that 
can perform effector T cell functions independently or help directing the function of other 
leucocytes. Naïve CD8+ T cells can differentiate into an effector cell type called cytotoxic T 
lymphocytes (CTLs). Activated B cells can differentiate into plasma cells that produce 
antibodies against infectious agents.  
A typical immune response starts when a microbe enters the body and encounters an innate 
immune phagocyte (macrophages, neutrophils or dendritic cells). The microbe is then 
recognized by PRRs on the phagocytic cells and is engulfed by phagocytes. The recognition 
of PRRs can induce an innate immune response that results in the killing of the microbe. In 
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the mean time some phagocytes can also process components of the microbes (antigenic 
peptides or antigens) to be loaded on the major histocompatibility complex molecules (MHC) 
on the cell surface for initiating adaptive immunity. These cells are called antigen-presenting 
cells (APCs). When T cell receptors (TCRs) on T cells recognize MHC-antigen complexes in 
addition to co-stimulatory signals presented by APCs, they become activated and initiate an 
adaptive immune response. Activated T cells perform a number of different tasks including 
direct killing of infected cells by CTLs and/or differentiate into many subsets of Th cells with 
effector functions to combat the offending microorganism (see section 1.4.3). Naïve B cells 
recognize antigen with their BCRs and sometimes with the help of Th cells, they get activated 
and differentiate into plasma cells, which secret antibodies to fight against infection.  
1.2 IMMUNOLOGICAL TOLERANCE 
The battle between the immune system and pathogens is a battle between “self” and “non-
self”. Although the immune system needs to recognize diverse types of foreign antigens that 
could be harmful to the body; it should also avoid miss-identification or overreaction that 
could disrupt normal physiology by mounting an erroneous or excessive immune response. 
To keep this delicate balance, an immune response should be tightly regulated so that in 
certain situations, a state of unresponsiveness of the immune system should be implemented 
so as not to elicit an immune response to harm “self”; such unresponsive state is referred to as 
immunological tolerance.  
Depending on the origin, immunological tolerance can be classified into central tolerance and 
peripheral tolerance. Central tolerance is induced in the thymus (for T cells) and bone marrow 
(for B cells). In the bone marrow, the immature B cells undergo negative selection where 
most of the autoreactive B cells that recognize self-antigen are deleted by the BCR-mediated 
apoptotic process of clonal deletion. In the thymus, those highly autoreactive thymocytes are 
also deleted during T cell development before they mature into immune-competent T cells 
(see section 1.4.1). Alternatively, some thymocytes that recognise self-antigens relatively 
strongly, but not strong enough to be negatively deleted, develop into a unique subset of T 
cells called regulatory T (Treg) cells, which can control potential lymphocyte autoreactivity 
in the periphery. Peripheral tolerance is induced after fully matured autoreactive T and B cells 
reach the peripheral tissue, these T and B cells can be rendered unresponsive either by 
aforementioned Treg cells, or through a state of “anergy” induced by the absence of co-
stimulatory signals and/or the presence of co-inhibitory signals. 
1.3 THE BIOLOGY OF DENDRITIC CELLS 
1.3.1 Antigen presenting cells and antigen presentation 
Antigen presenting cells are the bridge between the innate immune system and the adaptive 
immune system. For a T cell to recognize antigen, it requires the antigen to be processed and 
loaded on an MHC molecule. There are two classes of MHC molecules: class I and class II. 
MHC class I molecules (MHC-I) are expressed on almost all nucleated cells and are 
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specialize in presenting antigens from intracellular locations (endogenous antigens); MHC 
class II molecules (MHC-II) are restricted to APCs and are specialized in presenting antigens 
from extracellular spaces (exogenous antigens) that are taken up by APCs. Many cell types 
can function as APCs, however only a few cell types can express MHC-II as well as deliver 
co-stimulation signals to T cells, these APCs are referred to as professional APCs, including 
dendritic cells (DCs), macrophages and B cells. 
1.3.2 Dendritic cell subsets 
DCs are a very heterogeneous population and the ontogeny of DCs remains ambiguous. All 
blood cells originate from the same single cell type: the hematopoietic stem cells (HSCs) in 
the bone marrow. HSCs give rise to two broad progenitor lineages: the common myeloid-
erythroid progenitor (CMP) and the common lymphoid progenitor (CLP), both of which can 
generate dendritic cells.  
Historically dendritic cells can be divided into two groups: the classical dendritic cells (cDCs) 
and the plasmacytoid dendritic cells (pDCs), although neither group is a homogenous 
population in itself. cDCs are first discovered by Ralph Steinman and colleagues in the late 
1970s, and are well-known for their enhanced ability to capture, process and present 
phagocytosed antigens to T cells. pDCs earned their name for their plasma cell-like 
morphology in the 1990s. Besides their ability to present antigens, pDCs are specialized in 
rapid and massive production of type 1 IFN upon stimulation by foreign nucleic acids; 
therefore they are sometimes considered part of the innate immune system. 
As probably the most effective antigen presenting cell type, cDCs populate most of the 
lymphoid and nonlymphoid tissues. The phenotypical and functional distinction among 
different cDC subsets has not been an easy task. Extensive research on DCs has been 
performed on mouse models, and scientists have grouped cDCs based on both their location 
and expression of surface markers (Merad et al. 2013). Depending on the expression of 
surface markers, mouse cDCs can be divided into 3 subsets: the CD8α+ DCs, CD8α− DCs (or 
CD11b+ DCs) and Langerhans cells (LCs).  
Each subset of cDCs has distinct transcriptome profile, expression of PRRs and 
immunological functions. For example, CD8α+ DCs are the only cDCs that express TLR3 
and TLR11 (Edwards et al. 2003; Davey et al. 2010), they also express high levels of 
scavenger receptor CD36 (bind to dead cells) (Schulz et al. 2002; Belz et al. 2002), C-type 
lectin Clec9A (sense necrotic bodies) (Sancho et al. 2009), CD205 (take up apoptotic bodies) 
(Vremec et al. 2000) and langerin (Flacher et al. 2008). Therefore CD8+ DCs have the unique 
ability to divert exogenous antigen to a pathway that leads to antigen presentation on MHC-I 
molecules and activation of naïve CD8+ T cells, this process is called cross-presentation (den 
Haan et al. 2000; Pooley et al. 2001; Dudziak et al. 2007). On the other hand, CD8α− DCs are 
more programmed to prime CD4+ T cells. 
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1.4 THE BIOLOGY OF T CELLS  
1.4.1 T cell development 
T cells are developed from CLPs during hematopoiesis. After migrating from the bone 
marrow into the thymus, lymphoid precursors that are committed to the T cell lineage 
become thymocytes or immature T cells. These thymocytes then undergo different 
developmental stages to form mature T cells. In the early stage of T cell development, 
thymocytes are double-negative (DN) cells lacking both CD4 and CD8 expression on the cell 
surface. These DN cells then rearrange their T cell receptor (TCR) genes to become either 
TCRαβ T cells or TCRγδ T cells. The DN TCRαβ thymocytes also turn into CD4+CD8+ 
double-positive (DP) thymocytes and are ready for the thymic selection. Two distinct thymic 
selection processes are required for DP thymocytes to become mature T cells: positive 
selection selects thymocytes that are capable of binding self-MHC molecules, resulting in 
MHC restriction; and negative selection eliminates thymocytes that have too high affinity for 
MHC-self-peptide complexes, resulting in self-tolerance. Once a thymocyte survives the 
selection processes and makes a decision to be either CD4+ or CD8+ T cell, it leaves the 
thymus as a fully matured naïve T cell. In this thesis, I mainly focus on the biology of CD4+ 
T cells. 
1.4.2 Treg cell specificity 
Although the TCR repertoire of Treg cells is biased towards self, it remains possible that Treg 
cells can recognize exogenous antigens or become antigen-specific under particular 
immunological conditions. It has been reported in mice that natural Treg cells can respond 
specifically to pathogen-derived antigens when repeatedly exposed to Leishmania major 
infection (Suffia et al. 2006). In another mouse model containing a transgenic TCR P25 
specific for Mycobacterium tuberculosis (Mtb), Treg cell expansion can be observed in the 
affected lymph nodes after Mtb infection, and transferring Mtb-specific P25+ Treg cells 
purified from uninfected mice to Mtb infected mice could delay priming of effector T cell in 
the recipient mice (Shafiani et al. 2010). 
1.4.3 T cell activation 
A naïve T cell that just left the thymus and is constantly circulating and patrolling the system 
browsing for their cognate antigens. If the naïve T cell encounters an APC presenting a 
MHC-peptide complex that it can bind to sufficiently strong, it initiates an activation and 
differentiation program that produces a broad array of T cell subtypes that can fight against 
infection, this is called a primary immune response.  
For a naïve T cell to activate and differentiate into an effector T cell, three signals are 
required. Signal 1 is the engagement of antigen-specific TCR with the MHC-peptide 
complex, which is provided by the APCs that have encountered, internalized and processed 
antigens. The co-receptor CD4 or CD8 as well as adhesion molecules can further stabilize the 
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interaction between TCR and the MHC complex to allow long-term cell interactions and 
signalling. Signal 2 is the contact between a co-stimulatory receptor on the T cell with a co-
stimulatory ligand provided by a functional APC. There are positive co-stimulatory 
receptor/ligand and negative co-stimulatory (or co-inhibitory) receptor/ligand. A positive co-
stimulation helps to activate a naïve T cell when needed, while a negative co-stimulation (co-
inhibition) fine-tunes a T cell response to maintain peripheral tolerance and reduces 
inflammation. When signal 1 and signal 2 are present, the T cell is activated and starts to 
produce cytokines that facilitate cell cycle and proliferation. However, for a T cell to be fully 
equipped to fight against different types of pathogens and infection, it needs to further 
differentiate into an effector T cell, which requires assisting cytokines produces by APCs, T 
cells and many other immune cell types. These polarizing cytokines are sometimes referred to 
as signal 3. Signal 3 does not only enhance T cell proliferation but also determine which kind 
of effector T cell a naïve T cell should become. 
1.4.4 T cell differentiation and T helper cell subsets 
T cells can differentiate into many different functional subsets. After activation, CD8+ T cells 
differentiate into CD8+ cytotoxic T cells that can kill infected cells in the local tissues. CD4+ 
T cells become Th cells that orchestrate the activities of other cell types, such as B cells, 
macrophages and other T cells. Each subset of Th cells is dependent on signalling from 
distinct polarizing cytokines and expression of a transcription factor (the master gene 
regulator) that orchestrates transcription of the subset’s signature program (Fig. 1). Today 
many CD4+ T helper cell subsets have been documented, although some subsets are better 
characterized than others, such as Th1, Th2, Th17, Treg and follicular helper (Tfh) T cells.  
 
 
Figure 1: CD4+ effector T cell subsets differentiation. (Craft 2012) 
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IL-12, IL-18 and IFNγ promote the differentiation of Th1 cells, while IL-4 induces the 
differentiation of Th2 cells. In the periphery Treg cells can be induced from naïve T cells in 
the presence of TGFβ, while TGFβ together with IL-6 triggers the differentiation of Th17 
cells. On the other hand, IL-6 and IL-21 together activate T cells toward the Tfh lineage.  
Different Th cell subsets can also cross-regulate each other. The signature cytokines produced 
by each subset enhance their own differentiation while inhibit commitment to other helper T 
cell lineage. For instance Th1 cells produce IFNγ to inhibit proliferation of the Th2 subset, 
and IL-4 produced by Th2 cells down-regulates the production of IL-12 by APCs, thereby 
inhibiting Th1 differentiation. In a similar manner, while TGFβ up-regulates both FOXP3 
and RORγt, when IL-6 is present, the combined signals inhibit FOXP3 expression and 
promote the dominant expression of RORγt thereby Th17 differentiation. 
1.4.5 T cell memory 
After effector T cells clear the pathogens, a majority of them die by apoptosis, leaving only a 
small number of antigen-specific T cells to become memory T cells. This formation of 
memory cells is a big advantage of the adaptive immune system because memory cells can 
live quiescently in the body for a very long time. When they encounter the same antigens 
again, memory cells can mount a much faster, more robust and more effective secondary 
immune response. For example, CD4+ memory T cells require much lower dose of antigen 
for activation and much lower threshold for co-stimulation (Rogers et al. 2000; London et al. 
2000; Berard & Tough 2002). Memory T cells can be broadly divided into 2 subsets: central 
memory T cells (TCM) and effector memory T cells (TEM). TEM have already committed to an 
effector lineage and can respond very rapidly after reactivation. On the other hand, TCM live 
longer and maintain the capacity to differentiate into many effector T cell subsets after 
activation. Some surface markers are commonly used to distinguish naïve T cells, effector T 
cells and memory T cells. These surface markers are listed in Table 1:  
Cell type CD44 CD62L CCR7 
Naïve T cell Low + + 
Effector T cell + Low − 
Effector memory T cell + Variable − 
Central memory T cell + + + 
Table 1: Surface markers that are used to distinguish human naïve, effector and memory T cells. 
(Adapted from Kuby Immunology, 7th edition, by W. H. Freeman and Company, 2013)  
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1.5 THE BIOLOGY OF CD4+FOXP3+ REGULATORY T CELLS 
An important player for the maintenance of peripheral tolerance is the regulatory T cell 
population that suppresses immune responses in a dominant manner. Although this 
population was described as “suppressor T cells” as early as the 1970s (Gershon & Kondo 
1970), our understanding of this T cell population only became clearer when Sakaguchi and 
colleagues identified a population of CD4+ T cells expressing the IL-2 receptor α-chain 
(CD25) that are capable of preventing autoimmune diseases. These CD4+CD25+ T cells were 
then termed regulatory T (Treg) cells (Sakaguchi et al. 1995; Asano et al. 1996). A few years 
later, mutation of the gene Foxp3 encoding a forkhead/winged-helix transcription factor was 
identified to be responsible for the fatal autoimmune phenotype seen in scurfy mice 
(Brunkow et al. 2001) and human immune dysregulation, polyendocrinopathy, enteropathy, 
X-linked (IPEX) syndrome (Chatila et al. 2000; Bennett et al. 2001; Wildin et al. 2001). It 
was soon revealed that Foxp3 mRNA and protein were also predominantly expressed in the 
CD4+CD25+ Treg cell population and is the defining feature for CD4+CD25+ Treg cells. 
Loss-of-function mutation in Foxp3 gene resulted in developmental and functional 
impairment in Treg cells; on the other hand, forced expression of Foxp3 in CD4+CD25- T 
cells conferred a suppressive phenotype similar to that of CD4+CD25+ regulatory T cells 
(Hori et al. 2003; Fontenot et al. 2003; Khattri et al. 2003; Wan & Flavell 2005).  
To avoid any further confusion regarding studies done in human and mouse, in this thesis, the 
following simplified nomenclature is used: 
Species Gene mRNA or protein 
Human FOXP3 (italicized) FOXP3 
Mouse Foxp3 (italicized) FOXP3 
 
1.5.1 Treg cell development 
Treg cells can be differentiated intrathymically or extrathymically. Treg cells differentiated in 
the thymus are termed thymic derived (tTreg) cells. They emerge mostly at the CD4+CD8− 
single positive stage and make up the majority of total Treg cell pool. Sequencing studies in 
mice demonstrated that Treg cells and naïve T cells have very different TCR repertoire, 
moreover the TCR repertoire from Treg cells is specifically biased toward self-peptides and is 
also more diverse than naïve T cells (Hsieh et al. 2004; Pacholczyk et al. 2006). 
A TCR with high affinity for a self peptide is required for the development of Treg cells in 
the thymus (Jordan et al. 2001). This idea is supported by the observation that Treg cells 
display a higher degree of TCR ζ-chain phosphorylation than effector T cells (Andersson et 
al. 2007). However, affinity is not the only deciding factor. Other studies suggested that Treg 
cells selectively utilize a limited antigen niche for the development of tTreg cells (Bautista et 
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al. 2009). When self-antigen is expressed at low levels, it promotes the development of Treg 
cells. However when self-antigen is expressed at high levels, it predominantly results in 
negative selection (Picca et al. 2009). Therefore both antigen affinity and avidity play 
important roles in the development of tTreg cells. 
Alternatively, Treg cells can also be differentiated from naïve CD4+ T cells in periphery in 
vivo (pTreg cells) or induced from naïve CD4+ T cells in vitro (iTreg cells). For simplicity 
both of these two populations are referred to as induced Treg (iTreg) cells in this thesis. iTreg 
cells are required to uphold immune homeostasis. Mice deficient in a conserved non-coding 
DNA sequence (CNS1) that is important for de novo FOXP3 expression, develop Th2 type 
pathologies in lungs and intestines (Josefowicz, Niec, et al. 2012). 
Other factors such as co-stimulation and cytokine signalling also participate in Treg cell 
development. These are discussed more in detail in section 1.5.7.1. 
1.5.2 Identifying mouse and human Treg cells 
Many markers have been suggested in literatures for the identification of Treg population in 
humans and mice. Unfortunately none of these markers are specific for Treg cells, therefore a 
combination of different surface and intracellular molecules are commonly used, which I will 
discuss briefly below.  
1.5.2.1 FOXP3: the good and the bad 
Since its discovery, FOXP3 has been viewed as the master regulator and specific marker for 
Treg cells. However there is now substantial amount of evidence showing that FOXP3 is 
neither a reliable marker nor the sole regulator of functionally stable Treg population. It has 
been shown that conventional CD4+ T cells can transiently express FOXP3 under TCR 
stimulation while confer no suppressive activity both in human and mouse (Gavin et al. 2006; 
Allan et al. 2007; Tran et al. 2007; Wang et al. 2007; Miyao et al. 2012; Miyara et al. 2009). 
And functional Treg cells can lose FOXP3 expression in inflammatory or lymphopenic 
conditions and acquire the ability to produce pro-inflammatory cytokines (Zhou et al. 2009; 
Yang et al. 2008; Xu et al. 2007; Komatsu et al. 2009; Duarte et al. 2009). In addition, studies 
also demonstrated significant differences between bona fide Treg cells and FOXP3-
transduced conventional CD4+ T cell in terms of global gene expression patterns (Sugimoto 
et al. 2006; Hill et al. 2007). Collectively these findings suggest that although FOXP3 is 
crucial for the suppressive function of Treg cells, FOXP3 per se is not sufficient to define the 
lineage of functional Treg cells and additional mechanisms/molecules are required.  
1.5.2.2 Other markers used for Treg cell identification 
Given that FOXP3 alone is neither specific nor sufficient for delineating Treg population and 
the fact that it is an intracellular protein, which is not convenient for isolation of Treg cells ex 
vivo, other surface markers have been added in the panel. 
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CD25: For murine Treg cells, CD25 is a widely used surface marker for isolation of Treg 
cells (CD4+CD25+ T cells), however activated conventional CD4+ T cells can also up-
regulate CD25, which makes it important to use naïve mice in the study (Sakaguchi et al. 
1995). For isolation of human Treg cell isolation, CD25 is an even worse marker. Human 
CD4+ T cells express a gradient level of CD25 on the surface. Although human CD4+ T cell 
with the highest expression of CD25 have the strongest suppressive activity (Dieckmann et 
al. 2001), depending on the gating strategy, the CD4+CD25hi T cell population can get 
substantial contamination from the activated conventional CD4+ T cells (Baecher-Allan et al. 
2001; Allan et al. 2007; Miyara et al. 2009). On the other hand, if a more stringent gate is 
applied, the risk of missing the FOXP3+CD25low Treg population is also increased. 
IL-2: is a marker that is rarely used for identifying Treg cells but may be the most specific 
marker of all. The main advantage of IL-2 is that Treg cells are unable to produce IL-2 as 
FOXP3 represses IL-2 production in Treg cells. Therefore a FOXP3+ T cell that is unable to 
express IL-2 is a bona fide Treg cell. However, due to its intracellular location and the 
requirement for stimulation to induce IL-2 production, it is challenging to use IL-2 as a Treg 
cell marker in practise.  
CD127: also known as IL-7 receptor α-chain, is a useful alternative to CD25. Several studies 
suggested that Treg cells lack the expression of CD127, which makes it a good marker for 
isolation of human Treg cells in combination with CD25 (in which case Treg cells are 
defined as CD4+CD25hiCD127− cells) (Liu et al. 2006; Seddiki et al. 2006). However 
conventional CD4+ T cells also down-regulate CD127 expression after activation, which 
complicates the discrimination of Treg cells ex vivo (Mazzucchelli & Durum 2007; Aerts et 
al. 2008). 
CD62L: although not exclusively expressed by Treg cells, when combined with CD25 and 
CD127, can be useful for distinguishing recently activated T cells (CD4+CD62Llow) and Treg 
cells (CD25hiCD127lowCD62L+) (Hamann et al. 2000).  
CD45RA and CD45RO: A recent paper suggested to use CD45RO and CD45RA in 
combination with CD25 to further dissect the heterogeneity of human Treg cells (Miyara et 
al. 2009). In this study, the CD4+CD45RA+CD25lowFOXP3+ population represents naïve or 
resting Treg cells, which corresponds to murine tTreg cells from the thymus. When these 
resting Treg cells are activated, they up-regulate FOXP3 and convert to activated/effector 
Treg cells which are CD4+CD45RO+CD45RA−CD25hiFOXP3hi T cells. Conversely the 
CD4+CD45RA−CD25lowFOXP3low population represents activation-induced FOXP3-
expressing cells that transiently express FOXP3 in vitro and are not suppressive. 
Other markers used for the identification of Treg cells are listed in Table 2. These markers are 
usually related to Treg cell activation status, localization or suppressive function, and can be 
very useful for studying different subsets of Treg cells.  
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Table 2: Treg markers in human and mouse. (Sakaguchi et al. 2010) 
 
1.5.3 Treg cell function 
The cellular targets and exact programs of Treg cell-mediated suppression remain 
controversial. However it has become evident that Treg cells can utilize multiple approaches 
for their suppressive function (Shevach 2011). Although Treg cells can suppress many cells 
types, DCs and effector T cells are considered the major targets of Treg cell-mediated 
suppression.    
1.5.3.1 Modulation of DC maturation and function 
Treg cells can inhibit DC maturation in vitro by down-regulating or preventing the up-
regulation of co-stimulatory molecules CD80/CD86 on DC surface (Cederbom et al. 2000; 
Misra et al. 2004; DiPaolo et al. 2007). This effect is largely dependent on cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4, also known as CD152) (Wing et al. 2008; 
Qureshi et al. 2011). Treg cells can also inhibit the production of IL-6 while promoting the 
production of IL-10 and induction of the immunoregulatory enzyme indoleamine-2, 3-
deoxygenase (IDO) by DCs (Veldhoen et al. 2006; Grohmann et al. 2002). In addition in 
vitro and in vivo studies have demonstrated that Treg cells can decrease the contact between 
effector T cells and DCs prior to inhibition of effector T cell activation (Onishi et al. 2008; 
Tang et al. 2006; Tadokoro et al. 2006).  
1.5.3.2 Modulation of effector T cell function 
Treg cells can inhibit effector T cell proliferation by disrupting the metabolic pathways in 
effector T cells. For example, IL-2 is an important cytokine for T cell proliferation. In vitro 
experiment in mice demonstrated that Treg cells can inhibit IL-2 production in effector T 
cells in a cell-contact dependent manner thus limit effector T cell proliferation (Thornton & 
Shevach 1998). However the role of IL-2 in vivo remains controversial since complete IL-2 
knockout mice actually die from lymphoproliferative syndrome within 5 weeks of age 
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(Takacs et al. 1984; Jenkinson et al. 1987; Tigges et al. 1989; Sadlack et al. 1995). Treg cells 
can also interfere with effector T cell activation by hydrolysing adenosine triphosphate (ATP) 
into adenosine. This hydrolysis cascade is mediated by extracellular enzyme CD39 and CD73 
which are expressed both in human and murine Treg cells (Deaglio et al. 2007; Fletcher et al. 
2009; Dwyer et al. 2010; Alam et al. 2009; Kobie et al. 2006). Treg cells from CD39 
knockout mouse had a more than 50% of reduction in their ability to suppress effector T cell 
proliferation (Deaglio et al. 2007). In addition, the accumulation of adenosine can also act via 
adenosine A2A receptor (A2AR) and promote iTreg cells induction (Zarek et al. 2008). 
1.5.3.3 Production of anti-inflammatory cytokines 
Several studies suggested that the production of anti-inflammatory cytokine, such as TGFβ 
and IL-10, is an essential effector mechanism for Treg cells (Powrie et al. 1996; Nakamura et 
al. 2001; Fahlén et al. 2005; Asseman et al. 1999; Hara et al. 2001). A cell surface form of 
TGFβ, propeptide-latency-associated peptide (LAP), expressed by activated Treg cells can 
also induce Foxp3 expression in naïve CD4+Foxp3− T cells in a cell-contact dependent 
manner, this phenomenon is known as “infectious tolerance” (Andersson et al. 2008). 
Recently another cytokine IL-35 has also been implicated as a mediator for Treg cell 
suppression. However the exact role of IL-35 requires further investigation (Collison et al. 
2007; Collison et al. 2010; Collison et al. 2012). While Treg cells most certainly can produce 
anti-inflammatory cytokines, the relative importance of these cytokines in Treg cell-
dependent suppression remains to be determined. Both mice with TGFβ deficiency 
specifically in Treg cells and mice completely deficient in an IL-35 subunit p35 displayed no 
signs of spontaneous inflammatory disease (Gutcher et al. 2011; Collison et al. 2007). In 
contrast, mice deficient in IL-10 specifically in Treg cells develop inflammation in skin, lung, 
colon (Rubtsov et al. 2008). 
1.5.3.4 Target cell killing 
Except for anti-inflammatory cytokine production and modulation of DC and effector T cell 
functions, Treg cells can also kill target cells by inducing cytolysis and apoptosis. These 
cellular targets can be DCs, effector T cells, B cells and NK cells. For example human Treg 
cells express granzyme A and can mediate target-cell killing by granzyme A and perforin via 
the adhesion of CD18 (Grossman et al. 2004). Murine Treg cells showed similar granzyme-
B-dependent suppressive mechanism on effector T cell, B cells and NK cells (Gondek et al. 
2005; Zhao et al. 2006; Cao et al. 2007). In addition human Treg cells can kill autologous 
CD8+ T cells through Fas-mediated apoptosis (Strauss et al. 2009), and murine Treg cells 
were documented to induce apoptosis of effector T cells through a TRAIL–DR5 (tumour-
necrosis-factor-related apoptosis-inducing ligand – death receptor 5) pathway (Ren et al. 
2007). 
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1.5.4 Treg cell: stability vs plasticity  
As discussed in section 1.5.2, Treg cells is a highly heterogeneous population that could 
change their functional, migratory and homeostatic properties depending on the environment 
(Josefowicz, Lu, et al. 2012). And it has long been debated whether Treg cells are a 
functionally stable population or if they retain certain plasticity. It is also difficult to address 
whether such plasticity stems from the possibility that Treg cells can be re-programmed into 
other cell lineages (lineage plasticity) or they simple acquire other effector T cell 
characteristics temporarily to facilitate suppressive function in a particular setting (functional 
plasticity). Regardless, it was evident that the expression and maintenance of FOXP3 is at the 
centre of this debate, and that induction and maintenance of FOXP3 expression are two 
separate processes regulated by distinct mechanisms (Zheng et al. 2010).  
1.5.4.1 Evidences for plasticity 
Initial studies suggested that Treg cells are functionally stable due to the fact that they can 
maintain their suppressive capacity even after many rounds of proliferation and division 
(Annacker et al. 2000; Gavin et al. 2002; Fisson et al. 2003; Klein et al. 2003). However 
under lymphopenic or inflammatory conditions, Treg cells can lose FOXP3 expression and 
start to produce effector cytokines such as IFNγ, IL-2 and IL-17 (Zhou et al. 2009; Yang et 
al. 2008; Xu et al. 2007; Komatsu et al. 2009; Duarte et al. 2009). In addition, some murine 
FOXP3+ T cells can even lose FOXP3 expression upon prolonged TCR/CD28 stimulation or 
with co-stimulation signals (Vu et al. 2007; Degauque et al. 2008; Gabryšová et al. 2011), 
similar features have also been observed in human FOXP3+ T cells in vitro (Koenen et al. 
2008; Hoffmann et al. 2009). Under non-lymphopenic conditions, the instability of Treg cells 
has also been demonstrated. Using genetically modified fate-mapping mouse model, several 
groups showed that at least a fraction of FOXP3-expressing Treg cells lose their FOXP3 
expression in vivo or even become pathogenic (Miyao et al. 2012; Zhou et al. 2009; Bailey-
Bucktrout et al. 2013).  
In certain conditions, Treg cells can also acquire effector T cell-like features without losing 
FOXP3 expression. For example, when stimulating Treg cells under Th1 polarizing 
conditions in vitro, some FOXP3+ T cells express T-bet and IFNγ without losing FOXP3 
expression (Wei et al. 2009; Dominguez-Villar et al. 2011; Koch et al. 2012; Zhao et al. 
2012). These FOXP3+T-bet+IFNγ+ T cells can also be found in vivo in human disease 
conditions such as multiple sclerosis (Dominguez-Villar et al. 2011) or type I diabetes 
(McClymont et al. 2011) and in mice (Oldenhove et al. 2009; Zhao et al. 2011). 
FOXP3+RORγt+IL17+ T cells have also been identified in vivo both in human and mouse, 
especially in the intestine (Beriou et al. 2009; Voo et al. 2009; Zhou et al. 2008). 
1.5.4.2 Evidences against plasticity 
There are also contradictory observations that dispute the notion of Treg cell plasticity. One 
study using mouse experimental autoimmune encephalomyelitis (EAE) model demonstrated 
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that myelin oligodendrocyte glycoprotein (MOG)-specific FOXP3+ and FOXP3− T cells had 
very different TCR CDR3 sequences and were derived from distinct clones, indicating that 
these two populations had very limited inter-conversion, if any, during the autoimmune 
inflammation (Liu et al. 2009). Moreover Rudensky and colleagues also showed that in their 
genetic fate-mapping mouse model, FOXP3+ T cells are remarkably stable under steady state, 
and these sorted FOXP3+ T cells did not convert to FOXP3− T cells under autoimmune 
conditions in non-lymphopenic host mice (Rubtsov et al. 2010). 
1.5.4.3 Concluding remarks 
The above-mentioned studies cannot be easily reconciled with each other. However, it is clear 
that the Treg cell identity is not determined solely by a single factor, for example FOXP3. 
This notion is further supported by two recent studies where it was shown that FOXP3 
together with its cofactors form an interactive network with multiple circuitries and feedback 
loops, together this interactive network “locks-in” the characteristics of a Treg cell signature 
(Fu et al. 2012; Rudra et al. 2012). In addition, the epigenetic regulation play an important 
part in deciding Treg cell fate (Toker et al. 2013). Collectively these findings suggest that the 
Treg cell identity is shaped through an interactive transcriptional network that can self-
perpetuate as a whole. 
1.5.5 Treg cells in diseases 
1.5.5.1 Treg cells in infection 
To survive an infection, the host needs to clear the invading pathogens but also limit the 
extent of the immune response so as not to damage self-tissue. This is where Treg cells come 
into play as immune regulators. However, the outcome of Treg cell mediated suppression can 
be either beneficial or detrimental to the host depending on the properties of the invading 
pathogens as well as the location and phase of infection.  
Several studies using immuno-deficient animals demonstrated that Treg cells are needed for 
controlling the excessive immune response during an infection to limit collateral damage to 
host tissue (Suvas et al. 2004; Hesse et al. 2004). However, the suppressive activity of Treg 
cells may also cause unwanted consequences. In deed, too much suppression during an acute 
infection could hinder the protective immune responses and clearance of pathogens, which 
leads to either death or the prolonged survival of pathogens and persistence of infection. For 
example, in patients with chronic HIV infection, removal of CD4+CD25+ T cells enhanced 
anti-viral response and reduced viral load (Aandahl et al. 2004; Andersson et al. 2005). On 
the other hand, persistence of infection could also help the host to develop concomitant 
immunity that protects from reinfection. In a mouse model of persistent Leishmania major 
infection in the skin, after initial recovery from the first infection, Treg cells can suppress the 
CD4+CD25− effector T cell function via IL-10 dependent and independent mechanisms, 
thereby allowing parasite persistence and at the same time maintaining an efficient memory 
response to Leishmania major that protects the host from reinfection. 
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In summary, it seems that the role of Treg cells in infection is to establish a fine balance 
between the pathogen and its host that should benefit both. However if such balance were to 
be displaced, leading to excessive induction of Treg cells or alteration in Treg cell function, it 
would result in excessive replication of and damage by the pathogen that can overwhelm the 
host.  
1.5.5.2 Treg cells in cancer  
Cancer or malignant tumors refers to a group of diseases characterized by abnormal and 
uncontrollable cell growth with the potential of spreading to other parts of the body that 
damage normal physiological functions. One of the hallmarks of cancer is the ability to avoid 
immune destruction (Hanahan & Weinberg 2011). Treg cells may suppress anti-tumor 
responses since most tumor-associated antigens are derived from self proteins (Kawakami & 
Rosenberg 1997). On the other hand, Treg cells can also suppress inflammatory responses, 
which in turn predispose for the development of cancer. Thus the correlation between Treg 
cell numbers and cancer progression in patients remains ambiguous.  
Indeed, increased frequency of Treg cells is present in various types of cancers such as head 
and neck (Schaefer et al. 2005), lung (Wolf et al. 2003), liver (Ormandy et al. 2005), 
gastrointestinal tract (Ichihara et al. 2003), pancreas (Hiraoka et al. 2006), breast (Liyanage et 
al. 2002), ovary (Curiel et al. 2004) and malignant melanoma (Gerber et al. 2014) and the 
number of Treg cells are negatively related to disease progression in gastric cancer (Sasada et 
al. 2003), breast cancer (Bates et al. 2006) and ovarian cancer (Curiel et al. 2004; Sato et al. 
2005). However, other studies also demonstrated that increased number of Treg cells can 
associate with good prognosis, for example in head and neck cancer (Badoual et al. 2006), 
colon cancer (Salama et al. 2009) and Hodgkin lymphoma (Álvaro et al. 2005). 
1.5.5.3 Treg cells in autoimmune disorders 
An autoimmune disorder occurs when immunological tolerance is broken and the immune 
system starts to attack healthy body tissue by mistake, this includes diseases such as systemic 
lupus erythematosus (SLE), multiple sclerosis (MS), type 1 diabetes (T1D), rheumatoid 
arthritis (RA) and inflammatory bowel disease (IBD). Loss of tolerance due to Treg cells can 
be reflected in many ways: it could be caused by a reduction in Treg cell number in the 
circulation or at the site of inflammation, defects in Treg cell suppressive function, 
inappropriate Treg cell specificities, and/or instability of Treg cell lineage.  
For example, decreased Treg cell frequency as well as impaired Treg cell suppressive 
function were observed in MS patients (Viglietta et al. 2004; Haas et al. 2005; Kumar et al. 
2006; Venken et al. 2008). In T1D patients, although Treg cell numbers appeared to be 
unchanged, those Treg cell had imparied suppressive function (Lindley et al. 2005; Ferraro et 
al. 2011). The number of Treg cells in IBD patients varies depending on the disease 
progression (Maul et al. 2005), and reports suggest that some Treg cells may lose their 
suppressive function and differentiate into Th17 cells (Ueno et al. 2013). 
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1.5.5.4 Concluding remarks 
Many discrepancies exist regarding the role of Treg cells in disease progression and 
prognosis. This may due to a number of reasons: 
1. Human Treg cell population is not an homogenous population, and FOXP3 is not a 
perfect indicator for the presence of bona fide Treg cells (Miyara et al. 2009).  
2. It is the number of activated Treg cells, not the number of total Treg cells that matters. 
3. It is not given that suppression only occurs within the local tissue, and the number of 
antigen-specific Treg cells in secondary lymphoid tissues in many studies remain 
largely unknown.   
4. There are a number of technical concerns with the quantification of Treg cells in some 
studies. The specificity of certain commercial anti-FOXP3 antibodies remain 
questionable. 
To better evaluate the roles of Treg cells in diseases, it is necessary to dissect the functional 
differences between different subsets of FOXP3-expressing cells in the circulation and in the 
local tissue.   
1.5.6 FOXP3 and its isoforms 
The FOXP3 gene is located on the X chromosome. Both human and mouse FOXP3 genes 
contain 11 coding exons, and the exon-intron boundaries are identical across the coding 
regions between mice and human (Brunkow et al. 2001). Downstream of the promoter 
region, the FOXP3 gene also contains multiple evolutionally conserved non-coding sequence 
regions (CNS1, CNS2 and CNS3), which serve as enhancers that regulate gene expression. 
The FOXP3 protein consists of a proline-rich N-terminal domain (exons 2–4), a zinc finger 
and leucine zipper domain (exons 5–7) and a fork-head (FKH) domain (exons 9–11) (Fig. 2). 
 
Figure 2: the structure of FOXP3 gene and FOXP3 protein. 
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1.5.6.1 Requirements for FOXP3 expression 
Many transcriptional events govern the expression of FOXP3: TCR signalling, co-
stimulation/co-inhibition and cytokine receptors are essential for active transcription of 
FOXP3 gene (Fig. 3 and Fig. 4). 
TCR signalling pathways contribute to FOXP3 expression in both tTreg cells and iTreg cells. 
In mouse T cells, downstream of TCR signalling, nuclear factor-κb (NF-κB) signals through 
c-Rel that directly binds the promoter, CNS2 and CNS3 regions to allow Foxp3 transcription 
(Isomura et al. 2009; Long et al. 2009; Ruan et al. 2009; Zheng et al. 2010). In addition, the 
binding of cyclic-AMP-responsive-element-binding-protein (CREB) and activating 
transcription factor (ATF) to the CNS2 region in Foxp3 gene after TCR stimulation was also 
implicated in Foxp3 expression in the thymus (Kim & Leonard 2007). TCR signalling also 
induces the expression of the nuclear receptor 4a (Nr4a) family. These factors bind to the 
Foxp3 promoter region and induce Foxp3 expression (Fassett et al. 2012). In human T cells, 
TCR signalling results in the binding of nuclear factor of activated T cells (NFAT) and 
activator protein 1 (AP1) to the FOXP3 promoter and induction of FOXP3 expression 
(Mantel et al. 2006). 
In addition to TCR signalling, co-stimulation is necessary for FOXP3 gene expression. 
However, while CD28 stimulation of thymocytes induces the expression of Foxp3 in the 
thymus (Tai et al. 2005), strong co-stimulation provided by CD28 impairs Foxp3 expression 
and iTreg induction in the periphery (Benson et al. 2007). Unlike in the thymus, the induction 
of Foxp3 and iTreg cells in the periphery require co-inhibitory molecules such as CTLA-4 
(Zheng et al. 2006). 
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Figure 3: Signalling pathways involved in human FOXP3 expression. (Huehn et al. 2009) 
 
 
 
Figure 4: Transcription factors regulating mouse Foxp3 expression. (Huehn & Beyer 2015) 
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Last but not least, cytokine mediated signalling is also important for FOXP3 gene expression. 
Treg cells are absent in the mice deficient for the common cytokine-receptor γ-chain, which 
transmits signals mediated by IL-2 and many other cytokines. However IL-2 signalling is 
dispensable for the induction of Foxp3 in the thymus, which means other cytokines are 
involved in this effect (Fontenot et al. 2005). The signalling cascade following the 
engagement of IL-2 involves Janus kinase 1 (JAK1), JAK3 and signal transducer and 
activator of transcription 5 (STAT5), STAT5 binds to both the Foxp3 promoter and CNS3 
which induce and stabilize Foxp3 gene expression (Yao et al. 2007; Burchill et al. 2007). 
Although IL-2 is not needed for tTreg cell development in the thymus, it is required for 
TGFβ-mediated induction of Foxp3 in iTreg cells (Davidson et al. 2007). In mice TGFβ is 
important for tTreg cell development as well as the maintenance of Foxp3 expression and 
homeostasis of iTreg cells in the periphery (Marie et al. 2005; Liu et al. 2008; Ouyang et al. 
2010). The binding of SMAD3 downstream of TGFβ signalling is a prerequisite for the 
induction of Foxp3 expression in naïve CD4+ T cells (Tone et al. 2008; Zheng et al. 2010; 
Schlenner et al. 2012). Furthermore generation of iTreg induced by TGFβ can be further 
supported by retinoic acid (RA) produced by intestinal DCs (Mucida et al. 2007; Benson et 
al. 2007; Hill et al. 2008). RA can directly induce histone acetylation at Foxp3 promoter 
(Kang et al. 2007), recruiting RA receptors to CNS1 (Xu et al. 2010), or interferes with 
production of effector cytokine by memory T cells (Hill et al. 2008).  
1.5.6.2 Epigenetic control of FOXP3 expression 
Epigenetic processes are known to play a key role in gene regulation. DNA methylation and 
histone modification are two major epigenetic mechanisms for establishing and maintaining 
chromatin structures. Recent studies suggest that FOXP3 gene expression in Treg cells is also 
under epigenetic control. Treg cells present a distinct DNA methylation pattern and 
characteristic histione modifications (Ohkura et al. 2012). For example, in both human and 
mice the CpG sites in the promoter region of the FOXP3 gene are almost completely 
demethylated in Treg cells while conventional CD4+ T cells have dominantly methylation in 
the promoter region (Kim & Leonard 2007; Zheng et al. 2010; Floess et al. 2007). Permissive 
histone modifications were also identified at the Foxp3 promoter region in Treg cells but not 
in conventional CD4+ T cells (Rudra et al. 2009; Zheng et al. 2010; Sekiya et al. 2013). 
The CNS region in Foxp3 has non-redundant regulatory functions for Foxp3 transcription and 
is also under epigenetic control. CNS1 is a sensor for TGFβ and is important for iTreg cell 
development. It does not contain any CpG motifs, but enriched permissive histone 
modifications were found in both tTreg cells and iTreg cells and deletion of CNS1 led to 
defective generation of iTreg cells (Zheng et al. 2010; Sekiya et al. 2011). CNS2, also known 
as Treg-cell specific demethylated region (TSDR), is a CpG-rich element downstream of the 
promoter. Demethylation of CNS2 is critical for the stabilization of Foxp3 expression in Treg 
cells (Nagar et al. 2008; Polansky et al. 2008), on the other hand, methylation of CNS2 
prevent FOXP3 gene expression in non-Treg cells both in human and mouse (Zorn et al. 
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2006; Josefowicz et al. 2009). CNS3 is located downstream of the first coding exon. In Treg 
cells, this region is also enriched in permissive histone modification such as H3K4 mono- and 
dimethylation even before Foxp3 was expressed in thymocytes, suggesting that CNS3 may 
facilitate the opening of Foxp3 locus in Treg-precusors and is important for the initiation of 
Foxp3 expression in both tTreg and iTreg cells. (Zheng et al. 2010).  
1.5.6.3 Alternative splicing and FOXP3 isoforms 
Alternative splicing is a highly regulated biological process that affects gene expression 
resulting in multiple protein products from a single gene. This process uses precursor mRNA 
as matrix or occurs co-transcriptionally. During alternative splicing, the spliceosome, a 
macromolecular ribonucleoprotein complex, selects and recombines certain exons to produce 
multiple mRNA transcripts that give rise to multiple protein isoforms. Alternative splicing 
occurs in 95–100% of human genes and approximately 63% of mouse genes (Barbosa-
Morais et al. 2012; Merkin et al. 2012), which greatly expands proteome diversity and 
functions in vertebrates (Nilsen & Graveley 2010; Irimia & Blencowe 2012; Braunschweig et 
al. 2013). 
 
 
Figure 5: Human FOXP3 isoforms and functions. 
 
So far FOXP3 isoforms have only been identified in humans but not in mice, and in human 4 
FOXP3 isoforms have been described (Fig. 5): a full-length isoform that contains all exons 
(FOXP3fl), an isoform lacking exon 2 (FOXP3Δ2), an isoform lacking exon 7 (FOXP3Δ7) 
and an isoform lacking both exon 2 and exon 7 (FOXP3Δ2Δ7) (Walker et al. 2003; Kaur et 
al. 2010; Mailer et al. 2009). The structural differences among human FOXP3 isoforms lead 
to different biological functions. For example, while FOXP3fl and FOXP3Δ2 confer a 
suppressive ability to Treg cells in vitro, FOXP3Δ2Δ7 inhibit other FOXP3 isoforms in a 
dominant negative manner (Aarts-Riemens et al. 2008; Mailer et al. 2009). The function of 
FOXP3Δ7 remains unknown (Kaur et al. 2010). 
Human FOXP3 isoforms Protein weight         Function  
Full length   1 2   3   4   5   6   7   8   9   10   11  47 kDa                  Suppressive 
Δ2Δ7   1 3   4   5   6   8   9   10   11  40 kDa                  Non-suppressive 
Δ2   1 3   4   5   6   7   8   9   10   11  43 kDa                  Suppressive 
Δ7   1 2   3   4   5   6   8   9   10   11  44 kDa                  Unknown 
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1.5.6.4 Post-translational modification of Foxp3 
Post-translational modifications (PTMs) include phosphorylation, acetylation, ubiquitination, 
sumoylation, methylation, and hydroxylation. PTMs can regulate the function of many 
transcription factors (Xu et al. 2012) and PTMs such as ubiquitination, acetylation, and 
phosphorylation are now known to regulate FOXP3 function (van Loosdregt & Coffer 2014). 
Ubiquitination controls the balance between protein synthesis and degradation by adding one 
(monoubiquitination) or more (polyubiquitination) ubiquitin to the lysine residues of a target 
protein. Treating murine Treg cells with a pan-deubiquitinase inhibitor can significantly 
decrease FOXP3 protein level in Treg cells as well as their suppressive capacity (van 
Loosdregt et al. 2013).  
Acetylation is the process where an acetyle group is covalently added to a lysine residue or 
the N-terminus in a substrate protein. As both acetylation and ubiquitination are restricted to 
lysine residues, acetylation can inhibit ubiquitination and vice versa. Acetylation of FOXP3 
protein has been shown to affect both FOXP3 stability and its DNA binding capacity (Li, et 
al. 2007; Samanta et al. 2008; van Loosdregt et al. 2010). For example mutation in the lysine 
residues of FOXP3 FKH domain impaired FOXP3 DNA binding ability and altered 
transcriptional activity of FOXP3 as well as Treg-associated gene expression profiles (Liu et 
al. 2012). 
Finally, FOXP3 activity can also be regulated by phosphorylation. A recent study 
demonstrated that phosphorylation at Ser418 in the C-terminal DNA-binding domain of 
FOXP3 regulates Treg cell suppressive function, and that in rheumatoid arthritis, TNFα 
induces dephosphorylated of Ser418 thus impair Treg cell function (Nie et al. 2013). 
Several extracellular signals can regulate FOXP3 PTMs. For instance TCR stimulation can 
promote the translocation of HDAC6 to the cell nucleus where it deacetylates FOXP3 thereby 
increase FOXP3 polyubiquitination and degradation (van Loosdregt et al. 2010; de Zoeten et 
al. 2011; Beier et al. 2012). On the other hand, TGFβ can stabilize FOXP3 by increasing the 
expression of histone acetyltransferases p300, p300 acetylates FOXP3 thus prevents FOXP3 
from polyubiquitination (Liu et al. 2013; Ghosh et al. 2013; Xiao et al. 2014). Pro-
inflammatory cytokine TNFα increases the expression of protein phosphatase (PP1), which 
can dephosphorylate FOXP3 and decrease FOXP3 DNA binding capacity and transcriptional 
activity (Nie et al. 2013). In addition, the chemokine CC ligand 3 (CCL3), IL-6 and hypoxia 
can promote FOXP3 ubiquitination and degradation (Dang et al. 2011; van Loosdregt et al. 
2013; Chen et al. 2013). 
1.5.6.5 Foxp3-dependent transcriptional programs 
Studies on murine Treg cells identified more than 600 genes that consist a typical Treg cell 
signature, although part of the signature genes are not directly regulated by Foxp3 but rather 
co-regulated with Foxp3 (Hill et al. 2007). Proteomics study revealed that more than 300 
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proteins interact with FOXP3 and form a complex regulatory network. These interactions are 
involved in a large number of biological processes such as chromatin modification, chromatin 
or DNA binding, regulation of transcriptional activity, RNA binding, processing, splicing and 
metabolism (Rudra et al. 2012).  
The 4 functional domains of FOXP3 possess distinct ability to interact with a variety of 
molecules. The N-terminal domain is responsible for transcriptional repression; the zinc 
finger and leucine-zipper are important for FOXP3 homo-dimer or tetramer formation; the 
highly conserved FKH domain has the capacity to bind to DNA (Fig. 6).  
 
 
Figure 6: Schematic representation of some FOXP3 binding partners, their site of interactions and 
function. (Adapted from Lozano et al. 2013) 
 
For example, the Ikaros family member Eos interacts with FOXP3 N-terminal domain, and 
together with the C-terminal binding protein 1 (CtBP1), form an inhibitory complex that 
mediates Foxp3-dependent gene silencing in Tregs (Pan et al. 2009). FOXP3 exon 2, which is 
located in the N-terminal domain, can also interact with and suppress the activity of RORγt 
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and RORα thus inhibit Th17 differentiation (Ichiyama et al. 2008; Zhou et al. 2008). The N-
terminal domain is also known to interact with c-Rel, this interaction can suppress the up-
regulation of many cytokines such as IL-6, IL-12, IFNγ and IL-2 (Fraser et al. 1991; Liou & 
Hsia 2003) and also contributes to the nuclear translocation of FOXP3 (Bettelli et al. 2005; 
Loizou et al. 2011). In addition to binding to transcriptional factors, the N-terminal domain 
also interacts with enzymes that regulate FOXP3 PTMs. Histone acetyltransferase (HAT) 
TIP60 and histone deacetylase HDAC7 both interact with the N-terminal of FOXP3 and this 
interaction is required for FOXP3-mediated repression (Li et al. 2007).  
The zinc finger and leucine-zipper are needed for dimerization of FOXP3 which is required 
for FOXP3 function as a transcriptional factor (Chae et al. 2006; Song et al. 2012). The 
leucine-zipper also interacts with histone H1.5 and runt-related transcription factor 1 
(RUNXI) which represses the transcription of IL-2 and IFNγ genes (Mackey-Cushman et al. 
2011; Ono et al. 2007).  
Finally NFAT interacts with FOXP3 FKH domain, this interaction represses the expression 
of IL-2 and up-regulates Treg markers such as CTLA-4 and CD25 (Wu et al. 2006). Under 
certain circumstances hypoxia-inducible factor 1 (HIF-1α) can bind to the FKH domain of 
FOXP3 and promote FOXP3 degradation (Dang et al. 2011).  
1.6 T CELL CO-SIGNALING RECEPTOR SUPER FAMILY 
The co-signalling molecules belong to the immunoglobulin superfamily (IgSF) and tumor 
necrosis factor receptor superfamily (TNFRSF). These molecules send stimulatory or 
inhibitory signals to the T cells to fine-tune T cell activation. Many co-signalling molecules 
have been identified and extensively studied during the years, among which are CD28, 
CD80/CD86, CTLA-4, programmed cell death protein 1 (PD-1) and its ligands, inducible T-
cell co-stimulator (ICOS), glucocorticoid-induced TNFR-related protein (GITR), etc (Chen & 
Flies 2013). 
1.6.1 CTLA-4 and its isoforms 
The CTLA-4 gene is located on human chromosome 2 and mouse chromosome 1, 
respectively (Harper et al. 1991; Howard et al. 1991; Lafage-Pochitaloff et al. 1990). It 
contains 4 coding exons for 4 different functional domains: exon 1 encodes the leader 
peptide, exon 2 the ligand-binding site, exon 3 the trans-membrane region and exon 4 the 
cytoplasmic tail (Ling et al. 1999). Both the leader peptide and the ligand-binding site form 
the extracellular part of CTLA-4.  
1.6.1.1 CTLA-4 isoforms 
CTLA-4 transcripts can form isoforms due to alternative splicing, and different isoforms exist 
between human and mouse. In human three CTLA-4 isoforms have been described: a full-
length isoform that contains all exons (flCTLA-4), a soluble form that lacks exon 3 (sCTLA-
4) (Oaks et al. 2000; Huurman et al. 2007) and a third isoform that contains only exon 1 and 
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exon 4 (1/4CTLA-4). For murine cells, four isoforms have been identified. Except for the 
three isoforms mentioned before, there is a fourth isoform in murine cells, the ligand-
independent CTLA-4 isoform (liCTLA-4), which lacks exon 2 (Ueda et al. 2003). 
1.6.1.2 CTLA-4 expression  
The localization and translocation of CTLA-4 is high dynamic. CTLA-4 is primarily found in 
intracellular compartments. The cytoplasmic domain contains an intracellular localization 
motif that may regulate its surface expression and function during T cell activation (Leung et 
al. 1995). The expression of CTLA-4 in human and mouse naïve T cells is barely detectable. 
Upon activation, naïve T cells can rapidly express CTLA-4 on the cell surface (Alegre et al. 
1996; Jago et al. 2004) and the extent of CTLA-4 expression is determined by the strength of 
the TCR signal (Egen & Allison 2002). Murine Treg cells constitutively express high level of 
CTLA-4 both on the surface and intracellularly (Takahashi et al. 2000). Human Treg cells 
express CTLA-4 intracellular only after activation in vitro (Miyara et al. 2009). 
Curiously enough, in vitro studies on murine T cells suggested that the expression of 
liCTLA-4 and flCTLA-4 followed a reciprocal pattern in early T cell activation. While 
liCTLA-4 was found highly expressed in un-stimulated CD3+ T cells, it decreased its 
expression within 24 hours after TCR engagement and was induced again by 48 hours post-
TCR stimulation. On the contrary, flCTLA-4 was rapidly induced within 16 hours after T cell 
activation and plateaued 24 hours post-stimulation. In addition, the level of liCTLA-4 mRNA 
in the CD4+CD45RBlow cells from diabetes resistant mouse strain was 4 times higher than 
that of the susceptible strain (Vijayakrishnan et al. 2004). 
1.6.1.3 CTLA-4 function 
CTLA-4 is an important negative regulator of immune responses. It is a structural homologue 
of the co-stimulatory receptor CD28, but has a stronger affinity to CD80/CD86 than CD28, 
especially to CD80 (Freeman et al. 1991; Freeman et al. 1993; Harper et al. 1991; Linsley et 
al. 1991). This interaction is dependent on the extracellular binding domain of CTLA-4 
(Linsley et al. 1991; Linsley et al. 1994). Germline Ctla4-deficient mice develop lethal 
immune dysregulation and autoimmunity (Tivol et al. 1995; Waterhouse et al. 1995). In 
humans, polymorphism in the CTLA-4 gene is associated with many types of autoimmune 
diseases (Ueda et al. 2003; Gough et al. 2005).  
The exact mechanisms how CTLA-4 restrains T cell activation remain controversial. Studies 
so far suggested that CTLA-4 have both cell-intrinsic and cell-extrinsic functions. As cell-
intrinsic functions, the cytoplasmic tail of CTLA-4 can recruit phosphatases SHP-2 and 
PP2A, which leads to the inhibition of downstream TCR signalling (Marengère et al. 1996; 
Lee et al. 1998; Chuang et al. 1999; Chuang et al. 2000). Moreover, CTLA-4 can compete 
with CD28 for the binding of CD80/CD86 in the immunological synapses; this interaction 
leads to less activation of NF-κB, NFAT and AP-1, and inhibition of IL-2 production and T 
cell proliferation (Fraser et al. 1999; Olsson et al. 1999; Greenwald et al. 2002; Krummel & 
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Allison 1996). It has also been shown that the cytoplasmic tail of CTLA-4 is necessary for 
TCR hypo-signalling in Treg cells (Tai et al. 2012). 
The cell extrinsic function of CTLA-4 is mostly attributed to its ability to bind to 
CD80/CD86. Several studies have suggested that CTLA-4 can down-regulate CD80/CD86 
on APCs by either indirect suppression of the APCs (Fallarino et al. 2003; Onishi et al. 2008), 
possible signalling through CD80/CD86 (Wing et al. 2008), or removal of CD80/CD86 on 
the surface of APCs by trans-endocytosis (Qureshi et al. 2011; Hou et al. 2015).  
The expression of CTLA-4 on Treg cells is also vital for immune homeostasis. CTLA-4 is a 
target gene of FOXP3 transcriptional regulation (Wu et al. 2006; Zheng et al. 2007). Mice 
lacking CTLA-4 specifically in Treg cells phenocopy Foxp3 deficient scurfy mice and die 
from lympho-proliferative disease early in life (Wing et al. 2008). CTLA-4-intact Treg cells 
are capable of suppressing autoimmunity mediated by CTLA-4-deficient Teff cells (Kolar et 
al. 2009; Ise et al. 2010). The discovery of trans-endocytosis by CTLA-4 provided a 
mechanistic explanation for Treg-mediated suppression via CTLA-4, and some believed that 
this cell-extrinsic function is essential and sufficient for Treg cell-mediated suppression via 
CTLA-4 (Walker & Sansom 2015). However, it has been shown that the expression of 
liCTLA-4 in the diabetes-resistant mouse strain was fourfold higher than that of the non-
obese diabetic (NOD) mouse strain (Ueda et al. 2003). In addition, Bluestone and colleagues 
also demonstrated in a mouse T1D model that liCTLA-4-expressing Treg cells seemed to be 
suppressive and could reduce diabetes incidence in vivo (Stumpf et al. 2013). On the other 
hand, when a mutation was introduced to the cytoplasmic tail of CTLA-4 so that an amino 
acid residue (Tyrosine 201) was replaced by a valine that could not be phosphorylated, the 
suppressive function of Treg cells was impaired while effector T cell function remained intact 
(Stumpf et al. 2014). This raises further questions about the importance of the cell-extrinsic 
function of CTLA-4 on Treg cell-mediated suppression. 
1.6.2 PD-1 and its ligands  
Programmed death-1 (CD279) is another member of the T cell co-signalling receptor super 
family. Its negative role in immune regulation was discovered by the autoimmune-prone 
phenotype observed in Pdcd1−/− mice (Nishimura et al. 1999; Nishimura et al. 2001). PD-1 
has two ligands PD-L1 (B7-H1, also known as CD274) and PD-L2 (B7-DC, also known as 
CD273). Except for PD-1, PD-L1 can also bind to CD80 (Butte et al. 2007) while PD-L2 
does not bind to CD80. However, there are data suggesting that PD-L2 may have another 
unknown receptor except for PD-1(Wang et al. 2003). 
PD-1 can be expressed on T cells, B cells, natural killer T (NKT) cells, activated monocytes, 
and DCs. Activated effector T cells express PD-1 on the surface, however resting Treg cells 
highly express PD-1 in the intracellular compartment (Raimondi et al. 2006). PD-L1 is 
constitutively expressed by murine T cells, B cells, DCs and macrophages, and induced to 
high level by inflammation. However the expression of PD-L2 is more restricted than PD-L1, 
  25 
its expression can only be induced on DCs and macrophages (Yamazaki et al. 2002) and 
some subsets of B cells (Zhong et al. 2007). IL-4, IFNγ and GM-CSF are powerful inducers 
of PD-L2 (Yamazaki et al. 2002).  
Treg cells can promote tolerance by inducing iTreg cells via PD-L1 signalling (Amarnath et 
al. 2010; Amarnath et al. 2011; Francisco et al. 2009). Some studies in mice have shown that 
expression and signalling of PD-L1 but not PD-L2 on the dendritic cells are important for the 
induction of FOXP3+ regulatory T cell from CD4+FOXP3− T cells (Wang et al. 2008; 
Amarnath et al. 2011; Francisco et al. 2009) while other groups reported that PD-L1 and PD-
L2 are equally important for this effect (Fukaya et al. 2010). Studies using Pdl2−/− mouse 
model suggested that PD-L2 is important for inhibition of T cell activation as well as oral 
tolerance (Zhang et al. 2006), and it has irredundant functions in tuning Th cells and CTL 
responses (Shin et al. 2005) as well as promoting anti-tumour immunity in a PD-1-
independent mechanism (Liu et al. 2003). 
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2 STUDY AIMS 
The overall aim of this study is to understand how protein isoforms contribute to regulatory T 
cell function and to define the functional consequences of Treg cell-mediated suppression on 
dendritic cells. 
More specific aims for each paper were: 
Paper I -- To understand the regulation and functional consequences of FOXP3 isoform 
expression in chronic inflammatory diseases in human 
Paper II -- To generate and characterize an in vivo animal model where we can study the 
biology of FOXP3 isoforms, specifically the FOXP3Δ2Δ7 isoform 
Paper III -- To dissect the functional consequences of Treg cell-mediated suppression on 
dendritic cells and more specifically, how CTLA-4 contributes to Treg cell-mediated 
suppression on dendritic cells 
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3 MATERIAL AND METHODS 
3.1 ANIMAL MODELS 
3.1.1 Generation of Foxp3δ2δ7 mouse 
A target vector was designed in such a way that a Foxp3 cDNA lacking coding exon 2 and 7 
was inserted after the Foxp3 translation initiation ATG codon, the TGA stop codon was 
replaced with a 2A peptide-GFP cassette followed by a double polyadenylation signal (pA) 
and an FRT flanked Neo cassette. The sequence of the Foxp3δ2δ7-2A-GFP cassette was 
verified using DNA sequencing prior to subcloning into the target vector. The Foxp3δ2δ7-
2A-GFP-2xpA-Neo cassette was flanked by a 5’ homology arm that extended 4.61 kb 5’ to 
the site of the cassette insertion and a 3’ homology arm that extended 2.05 kb 3’ to the site of 
the Neo cassette insertion, both of which were derived from a C57BL/6 BAC clone 
(RP23:54C14). Ten micrograms of the targeting vector was linearized using Not I and then 
transfected into BA1 (CD57BL/6 x 129/SvEv) hybrid embryonic stem cells by 
electroporation. After selection with G418 antibiotic, positive clones were screened by PCR 
and southern blotting analysis. Finally, the Foxp3 knock-in mice were bred with FLP delete 
mice to remove the Neo cassette, the resulting chimeras were further inbred to obtain mice 
that have the Neo deletion transmitted in the germ cells, yielding Foxp3δ2δ7 mice. 
3.1.2 Generation of Ctla4ex2fl/flFoxp3-Cre mouse 
A 8.9kb targeting vector was designed so that the long homology arm extends 6.01 kb 5’ to 
the single LoxP site. The short homology arm extends 2.02 kb 3’ to the LoxP/FRT-flanked 
Neo cassette. The single LoxP site is inserted 249 bp upstream of exon 2 of Ctla4 gene in 
intron 1-2, and the LoxP/FRT-flanked Neo cassette is inserted 271 bp downstream of exon 2 
in intron 2-3. The designed vector was subcloned from a positively identified C57BL/6 BAC 
clone (RP23:388N14) by homologous recombination-based technique. The BAC was then 
sub cloned into a ~2.45 kb pSP72 (Promega) backbone vector containing an ampicillin 
selection cassette for retransformation of the construct prior to electroporation. A pGK-gb2 
LoxP/FRT-flanked Neomycin cassette was inserted into the Ctla4 gene. The targeting 
construct was linearized using NotI prior to electroporation into embryonic stem (ES) cells. 
ES cells were then microinjected into Balb/c blastocysts. To remove the Neo cassette and to 
obtain Ctla4ex2fl/fl mice, the chimeras from the ES cells were mated with C57BL/6 FLP mice. 
The Ctla4ex2fl/fl mice were then bred with Foxp3-Cre mice to yield Ctla4ex2fl/flFoxp3-Cre mice. 
3.2 ACCQUISITION OF PATIENT SAMPLES 
Human peripheral blood and biopsies from affected areas of the rectum and sigmoid colon 
were obtained from patients diagnosed with Crohn’s disease. Disease activity was graded 
according to the simplified endoscopic activity score for Crohn’s disease as previously 
described (Daperno et al. 2004). A subgroup of patients was treated with anti-TNFα 
antibodies, infliximab (Remicade®) or adalimumab (Humira®). Anti-TNFα treatment was 
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administered either as intravenous injections of 5mg/kg infliximab at week 0, 2 and 6, or as 
subcutaneous injections of 80mg adalimumab at week 0 followed by 40mg adalimumab 
every other week. The Harvey-Bradshaw Index was used for assessment of patients’ response 
to the treatment (Harvey & Bradshaw 1980). Patients with a decrease of ≥3 points in clinical 
index activity score were considered as responders to the treatment. The choice of treatment 
for individual patient was based on clinical evaluations and considerations without any 
intervention from the study. 
3.3 CELL PREPARATION AND PURIFICATION 
3.3.1 Isolation of mouse CD4+CD25+ regulatory T cells 
Single-cell suspension was prepared from mouse peripheral lymph nodes. CD25+ T cells 
were enriched by AutoMACS positive selection using anti-mouse CD25-PE antibody and 
anti-PE MicroBeads. Enriched CD25+ T cells were then stained with anti-mouse CD4-APC 
antibody and high purity mouse CD4+CD25+ Treg cells were sorted using flow cytometric 
cell sorting (FACS JAZZ, BD). 
3.3.2 Isolation of mouse CD11c+ dendritic cells 
Single-cell suspension was prepared from mouse spleens. B cells, T cells and NK cells were 
depleted with a cocktail of biotin-conjugated antibodies and Anti-Biotin MicroBeads 
(Miltenyi Biotec). High purity CD11c+ dendritic cells were positively selected from the 
unlabeled fraction with mouse CD11c MicroBeads (Miltenyi Biotec). 
3.3.3 Isolation of mouse CD4+CD25- T cells 
Single-cell suspension was prepared from mouse peripheral lymph nodes. CD25+ T cells 
were depleted using anti-mouse CD25-PE antibody and anti-PE MicroBeads (Miltenyi 
Biotec). CD4+ T cells were then positively selected from the unlabeled fraction with mouse 
CD4 MicroBeads (Miltenyi Biotec). 
3.3.4 Isolation of human T cells 
Single-cell suspension was prepared from human PBMCs using Ficoll-Paque Plus gradient 
centrifugation (GE Healthcare).  
For isolation of human Treg cells, CD4+ T cells were positively selected from PBMCs with 
human CD4 MicroBeads (Miltenyi Biotec) using an AutoMACS Separator. The enriched 
CD4+ T cells were then stained with anti-human CD4, CD25, CD127 antibodies and 
CD4+CD25hiCD127low Treg cells were sorted using a FACSJazz instrument (BD 
Biosciences). 
Naïve CD4+ T cells were enriched from PBMCs by depleting non-T helper cells and memory 
CD4+ T cells using naïve CD4+ T cell Isolation Kit II (Miltenyi Biotec) according to the 
manufacturer’s instructions. The enriched CD4+ T cells were then stained with anti-human 
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CD4, CD25, CD45RA and CD62L antibodies and high purity (>95%) 
CD4+CD25−CD45RA+CD62L− naïve T cells were obtained by cell sorting using a FACSJazz 
instrument (BD Biosciences). 
3.4 IN VITRO CELL CULTURE 
Sorted CD4+CD25+ Treg cells were activated with 5ug/ml plate-bound anti-mouse CD3 
antibody and 500U/ml recombinant IL-2 (Biolegend) for 3 days and rested in complete 
medium with 500U/ml recombinant IL-2 for 24 hours. Pre-activated Treg cells were then 
cultured with purified splenic CD11c+ dendritic cells in a 1:1 cell ratio with 100ng/ml LPS 
for 24 hours. 24 hours later, CD11c+ dendritic cells were re-sorted from the DC-Treg co-
culture using flow cytometric cell sorting, and were either analyzed by flow cytometry or co-
cultured again with CD4+CD25− effector T cells (DC: T cell ratio = 1:10) for 3 days in the 
presence of 0.25ug/ml soluble anti-mouse CD3 antibody. 
3.5 HUMAN TH17 CELL DIFFERENTIATION IN VITRO 
Sorted naïve T cells were activated with 5ug/ml plate-bound anti-human CD3 and 1ug/ml 
soluble anti-human CD28 antibodies in X-VIVO 15 serum free medium supplemented with 
1% Penicillin-Streptomycin (Lonza) and 300U/ml recombinant human IL-2 (Peprotech). For 
differentiation towards the Th17 lineage, activated naïve T cells were cultured in addition 
with 10ng/ml TGFβ, 10ng/ml IL-1β, 25ng/ml IL-6 and 10ng/ml IL-23 (all from Peprotech) 
for 6 days. Four hours prior to harvesting, cells were re-stimulated with 50ng/ml PMA 
(Sigma) and 1ug/ml ionomycin (Life Technologies) and treated with GolgiBlocker (BD 
Biosciences). 
3.6 SPLICE-SHIFTING OF HUMAN T CELLS IN VITRO 
Enhanced FOXP3 exon splicing in human T cells was achieved by using Fluorescein-labeled 
Morpholino Antisense Oligonucleotides (MAO) with the following sequences (GeneTools):  
FOXP3ex1/3: 5’-TGCCCATTCACCGTCCATACCTGGT-3’  
FOXP3ex6/8: 5’-AGCTGTGAAATGGCACAAACATGAG-3’ 
Control: 5’-CCTCTTACCTCAGTTACAATTTATA-3’ 
Prior to activation, T cells were transfected with 15 µM MAO using the P3 Primary Cell 
Nucleofector Kit in a Nucleotransfector device (Lonza) according to the manufacturer’s 
instructions. 
3.7 EXPANSION OF REGULATORY T CELLS IN VIVO 
The protocol for in vivo expansion of Treg cells using IL-2/IL-2 mAb is as previously 
described (Boyman et al. 2006). In brief, wild type C57BL/6 mice were injected i.p daily with 
either 5ug isotype control (Biolegend) or 1ug recombinant mouse IL-2 (Biolegend) mixed 
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with 5ug anti-IL-2 mAb (Clone: JES6-1A12, Biolegend) for 3 days. Spleens from the 
injected mice were harvest on day 5 post-injection for FACS staining. 
3.8 QUANTITATIVE PCR 
Total RNA from T cells was isolated with Trizol (Life Technologies) and cDNA was 
generated using Vilo cDNA Synthesis Kit (Life Technologies). Amplification was performed 
with the following protocol: 2 min in 95°C, (15 sec in 95°C, 45 sec in 58°C, 30 sec in 68°C) 
x 39 cycles with iQ SYBR Green Supermix (Bio-Rad). Gene specific primer pairs are listed 
below: 
FOXP3ex1/2 sense: 5’-CAGCTGCAGCTGCCCACACTG-3’  
FOXP3ex1/2 antisense: 5’-GCCTTGAGGGAGAAGACC-3’  
FOXP3ex1/3 sense: 5’-CAGCTGCAGCTCTCAACGGTG-3’  
FOXP3ex1/3 antisense: 5‘-GCCTTGAGGGAGAAGACC-3’  
FOXP3ex6/8 sense: 5’-GAGCAGCAGGCA TCA TCCG-3’  
FOXP3ex6/8 antisense: 5’-CTGGGAA TGTGCTGTTTCC-3’ 
Relative gene expression was normalized by housekeeping gene GAPDH (ex vivo samples) 
or HPRT1 (cell culture samples). Primer specificity was confirmed by single peak 
performances of PCR products in melt curve analysis. Expression of FOXP3 splice variants 
was adjusted according to individual primer pair efficiency. Total FOXP3 mRNA expression 
was calculated as the sum of FOXP3ex1/2 and FOXP3ex1/3 and percentage of splice variant 
expression was calculated as (FOXP3 variant mRNA expression/total FOXP3 mRNA 
expression)*100. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
The key findings in paper I are: 
1. FOXP3 isoforms are differentially regulated in pro-inflammatory conditions such as 
Crohn’s disease. Comparing to healthy donors, patients suffering from Crohn’s 
disease had higher expression of FOXP3 isoform mRNA that lacks exon 7 
(FOXP3ex6/8) while the expression of total FOXP3 mRNA remained unchanged.  
2. The increase in FOXP3ex6/8 mRNA is correlated with disease severity. When 
patients were successfully treated with anti-TNFα antibody, there was a decrease in 
the percentage of FOXP3ex6/8 isoform transcripts in the biopsies. The increased 
splicing of exon 7 was also correlated with IL-17A expression in the biopsies in vivo, 
indicating that pro-inflammatory environment can alter the expression of FOXP3 
isoforms. 
3. When tested in vitro, we found that IL-1β, but not IL-6 or TNFα, was able to promote 
the splicing of exon 7 in Treg cells in combination with TCR stimulation. 
4. When altering FOXP3 isoform expression in naïve T cells in vitro in a Th17 
polarizing condition, increased expression of FOXP3ex6/8 isoform promoted Th17 
differentiation of naïve T cells.  
Exon 2 of FOXP3 belongs to the repressor domain, and the removal of exon 2 could disrupt 
the interaction between FOXP3 and its binding partners. For example it has been known that 
TGFβ together with other cytokines can regulate the differentiation of Treg and Th17 cells by 
balancing the expression of FOXP3 and RORγt. FOXP3 can directly bind to and antagonize 
the function of RORγt thus inhibit Th17 differentiation and the binding of RORγt is largely 
dependent on exon 2 of FOXP3, although a full inhibition of RORγt also requires the FKH 
domain (Ichiyama et al. 2008; Zhou et al. 2008). A recent study also suggested that a fully 
conserved 4-amino-acid motif in the N-terminal region of FOXP3 exon 2 is highly important 
for FOXP3 function, and that FOXP3 regulates gene expression mostly independent of direct 
DNA binding (Xie et al. 2015).  
These data do not fit with other papers showing that removing exon 2 of FOXP3 did not 
affect FOXP3 suppressive function. However these functional studies on FOXP3Δ2 isoform 
were performed in in vitro cell cultures often with over-expression of a certain isoform in 
transfected cells (Aarts-Riemens et al. 2008; Allan et al. 2005; Smith et al. 2006). It is 
possible that this artificial system does not reflect the true nature of FOXP3 function as such 
discrepancies have been observed between freshly isolated FOXP3+ Treg cells and 
conventional T cells transduced with FOXP3 (Sugimoto et al. 2006; Hill et al. 2007). 
FOXP3 exon 7 is part of the leucine-zipper domain and participates in the dimerization of 
FOXP3. Mutations within the leucine-zipper domain disrupt FOXP3 dimerization and 
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significantly reduce FOXP3 binding capability to the promoter regions of its target genes in 
vivo (Li et al. 2007; Lopes et al. 2006; Song et al. 2012; Chae et al. 2006). In addition the 
acetylation of two lysine residues (K250 and K252) in exon 7 has been proposed to stabilize 
FOXP3 (Song et al. 2012), however in our hands FOXP3Δ2Δ7 from MAO-treated Treg cells 
appeared to be stable and maintain DNA binding capacity.  
Both FOXP3 exon 2 and exon 7 are associated with Treg-mediated suppressive programs on 
other gene transcription such as IL-2, the removal of both exon 2 and exon 7 could release 
FOXP3 repression on other transcriptional factors and promote the expression of IL-2. 
All the factors above could potentially explain the loss of suppressive function by 
FOXP3Δ2Δ7 isoform. More interestingly, we found that IL-1β promotes the exclusion of 
FOXP3 exon 7. Previous studies have demonstrated that Helios−FOXP3+ Treg cells down-
regulate their suppressive functions in response to IL-1β (Raffin et al. 2013), and Treg cells 
exposed to both IL-1β and IL-2 differentiate into pro-inflammatory Th17 cells (Deknuydt et 
al. 2009). These data collectively suggest a role of pro-inflammatory cytokines in alternative 
splicing of FOXP3 and Treg cell function.  
It is not clear how the pattern of isoform expression looks like on a single cell basis. It is 
possible that each Treg cell is capable of expressing all forms of FOXP3 isoforms 
simultaneously, and when encountering environmental stimuli, it shifts the isoform 
expression pattern towards a particular isoform, and the changes in the balance of isoform 
expression alter Treg cell function. It is also possible that individual Treg cells exclusively 
express one type of FOXP3 isoforms, thus forming subsets of Treg cells with different 
functions. However, the flow cytometry data we obtained in FOXP3 isoform staining 
indicated that the former scenario is more likely. Evaluating FOXP3 isoform expression on a 
single cell level would be really interesting and would provide refreshing clues into the 
connection between alternative splicing and immune regulation by Treg cells. In addition, 
identifying the binding partners of individual FOXP3 isoform can further deepen our 
knowledge in understanding how FOXP3-dependent and/or independent transcriptional 
programs regulate Treg cell mediated suppression. 
The study on human FOXP3 isoforms is also limited by the methods available today. Flow 
cytometry is commonly used to measure expression of various surface and intracellular 
proteins. However currently the antibodies recognizing different FOXP3 isoforms are very 
limited (Fig. 7). The currently available antibodies can only detect the presence or absence of 
FOXP3 exon 2, and there is no antibody available that is specifically targeting exon 7. 
Therefore we can only indirectly visualize the expression of FOXP3Δ2 or FOXP3Δ2Δ7 in 
flow cytometry and alternative methods for FOXP3 isoform detection are needed. 
  35 
 
Figure 7: Schematic representation of the FOXP3 protein and the location of the epitopes for each 
anti-FOXP3 antibody clone. (www.ebioscience.com) 
 
Western blot is another alternative for protein detection. Analysis of FOXP3 isoforms in 
western blot reveals 3 bands, however the middle band is a composite band of both 
FOXP3Δ2 and FOXP3Δ7 as they have very similar sizes (43kDa and 44kDa respectively). 
Therefore it is still difficult to get precise quantification of FOXP3 isoforms using western 
blot. In addition, FOXP3 contains two RXXR proprotein convertase motifs that can be 
cleaved, resulting in multiple proteins derived from a single FOXP3 isoform (Elhage et al. 
2015). Taken all these into account it is almost impossible to get good quantitative data from 
western blot analysis of FOXP3 isoforms. 
Northern blot can be used for inter-molecular comparisons. While challenging to use to 
analyse patient samples with limited quantity, it may be worthwhile to analyse FOXP3 
transcript composition by using northern blot on in vitro cultured Treg cells. A concern here 
is that not only would we identify FOXP3fl, FOXP3Δ2, FOXP3Δ7 and FOXP3Δ2Δ7 but also 
differences in the transcripts that arise from alternative splicing of un-translated FOXP3 
exons. 
Due to the limitations presented above and the fact that we could only get access to very 
limited amount of patient samples in the study, we used quantitative PCR (qPCR) as our main 
method of detection for the expression of different FOXP3 isoform transcripts. Quantitative 
PCR has been used extensively to make inter-molecular comparisons of different splice-
variants (Shukla et al. 2011; De Arras & Alper 2013) given that the results are compensate 
for the differential efficiencies of distinct primer pairs. Therefore we believe that comparison 
of different FOXP3 isoform transcripts using qPCR are valid and in line with several other 
published studies, although it only reflects the expression of different isoforms on an mRNA 
level.  
RNA sequencing would be an excellent alternative to qPCR. If the experimental conditions 
are optimized, not only could it help us to quantify isoform expression in Treg cells, it could 
also be used to identify the differences in transcriptional programs initiated by individual 
FOXP3 isoforms. These results can be further compared with databases from published 
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results and would greatly enhance our understanding in the regulation of FOXP3 expression 
and Treg cell function in general.   
We hope that in the future specific antibodies against different FOXP3 epitopes can be 
developed, in particular an antibody recognizing the neo-epitope generated by combining 
FOXP3 exon 6 and 8. This would be helpful for checking FOXP3 splicing in subpopulations 
of Treg cells, including populations that simultaneously express multiple lineage-defining 
transcription factors such as FOXP3, T-bet and RORγt. In addition, more cost-efficient next 
generation sequencing techniques, especially on single cell level would vastly enrich our 
knowledge in the role of FOXP3 alternative splicing in Treg cell biology. 
4.2 PAPER II 
The key findings in Paper II are: 
1. We developed a mouse model with a knockin construct where exon 2 and exon 7 
were removed from the Foxp3 transcript, resulting in a mouse that only expresses a 
mouse version of FOXP3 isoform—Foxp3δ2δ7. While heterozygote female 
Foxp3δ2δ7/X mice appear perfectly healthy, the homozygote males (Foxp3δ2δ7/Y) died 
from lymphoproliferative disease starting from 3 weeks of age. 
2. Upon closer examination, homozygote males (Foxp3δ2δ7/Y) phenocopied Foxp3-
deficient scurfy mice with multi- organ inflammation, splenomegaly, 
lymphadenomegaly, profound T cell activation, impaired B cell development, 
autoantibody production and activated APCs. 
One concern with this study is that the targeting construct we used to replace the Foxp3 gene 
resulted in the deletion of CNS3 in the Foxp3 promoter, as it is located after the first coding 
exon. However, since CNS3 deficient mice display normal levels of Treg cells in lymph 
nodes and only slightly reduced numbers in spleen (Zheng et al. 2010), we consider this 
impact of CNS3 deletion unlikely in our model. Another worthwhile comparison would be 
between the Foxp3δ2δ7 mouse and a Foxp3δ2 mouse model that only lacks exon 2. This could 
give us a clue as how removal of different exons in FOXP3 affects Treg cell function in vivo. 
The reason why we choose mouse models to study FOXP3 function is because FOXP3 gene 
is highly conserved between species, especially since human FOXP3 confers suppressive 
function when transfected into murine cells in vitro. However, we do not know if similar 
analogy can be made for FOXP3 isoforms. Alternative splicing is very species-specific 
(Barbosa-Morais et al. 2012). Although sequencing studies indicated that the exon-intron 
boundaries are identical across the coding regions of the mouse and human FOXP3 genes 
(Brunkow et al. 2001), the differences in alternative splicing regulators may lead to 
completely different isoform patterns in different species. Interestingly, a recent paper 
suggested that mouse FOXP3 may indeed be alternatively spliced, although the resulting 
isoform is very different from any of the known human FOXP3 isoforms (Ergun et al. 2013). 
Despite all these, the FOXP3δ2δ7 mouse can still be a useful model for studying FOXP3 
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isoforms in vivo. Another alternative would be to use humanized mice where we engraft a 
human immune system into an adult immune-deficient mouse. It would be interesting to see 
if alternative splicing in human Treg cells would occur in the recipient mouse the same way 
as in a human body, and if so, how these isoforms function in vivo. 
4.3 PAPER III 
The key findings in Paper III are: 
1. We generated a transgenic mouse model—the Ctla4ex2fl/flFoxp3-Cre mouse where 
CD4+Foxp3+ T cells in these mice exclusively express ligand-independent CTLA-4 
that lacks the extracellular domain encoded by Ctla4 exon 2. The expression of 
CTLA-4 on other T cell populations was not affected. 
2. Ctla4ex2fl/flFoxp3-Cre mice were generally healthy, but slowly developed 
inflammatory lesions in the lung starting at 4–6 months of age.  
3. Ctla4ex2fl/flFoxp3-Cre mice had significantly increased frequency of CD4+CD25+ Treg 
cells in the spleen, and these Treg cells were also highly proliferative. Moreover, in 
the thymus of young Ctla4ex2fl/flFoxp3-Cre mice there was also increased frequency of 
Foxp3+ thymocytes in both CD4+CD8+ and CD4+CD8− compartments. 
4. In vitro experiments revealed that Treg cells from Ctla4ex2fl/flFoxp3-Cre mice were 
just as potent as wild type Treg cells in preventing the up-regulation of CD80/CD86 
on activated DCs, and decreasing DCs’ ability to support effector T cell proliferation. 
5. Interestingly, we also found that DCs co-cultured with wild type Treg cells could up-
regulate PD-L2, while Treg cells from Ctla4ex2fl/flFoxp3-Cre mice could not do so. 
Moreover the up-regulation of PD-L2 was more prominent in the CD8α+ DCs. 
It has long been thought that trans-endocytosis is an important mechanism for CTLA-4 
mediated suppression by Treg cells. However, several studies also indicated that this is not 
the only function of CTLA-4. The overall healthy status of Ctla4ex2fl/flFoxp3-Cre mice 
demonstrated again that Treg cell mediated suppression via CTLA-4 is not just about trans-
endocytosis. However, Ctla4ex2fl/flFoxp3-Cre mice did develop mild inflammation in the 
environmental surfaces such as the lung and intestine, demonstrating that liCTLA-4 in Treg 
cells alone cannot function perfectly to maintain immunological homeostasis, This could 
either be a result of the lack of cell-extrinsic Treg cell-mediated CTLA-4 signalling or 
insufficient signalling from CTLA-4 into the Treg cell. While liCTLA-4 can signal in cis, this 
signal presumably is weaker than when CTLA-4 binds to CD80 or CD86. This observation 
has also been implicated in other studies that it requires T cells to express both flCTLA-4 and 
liCTLA-4 to function properly (Stumpf et al. 2013). 
The increased thymic output of Treg cells contradicts a prior study where exons 2 and 3 of 
CTLA-4 were flanked by LoxP sites, resulting in complete deletion of CTLA-4 in Treg cells 
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when bred with Foxp3-cre mice (Wing et al. 2008). This discrepancy could be a result of 
different efficiency in Ctla4 deletion. Double-positive thymocytes from the Ctla4ex2fl/flFoxp3-
Cre mice almost completely lacked expression of the extracellular region of CTLA-4, while 
both single-positive and double-positive thymocytes from Ctla-4ex2-3fl/flFoxp3-Cre mice only 
displayed partial deletion of CTLA-4 in the thymus. Several other studies have addressed the 
impact of CTLA-4 on thymic development of Treg cells, but their results are contradictory. 
Those studies utilized mice completely devoid of CTLA-4, and the results might therefore be 
influenced by indirect changes in the thymic microenvironment, as both cytokines and 
adhesion molecules modulate thymic selection. 
The in vitro suppression assay demonstrated that liCTLA-4 on Treg cells were just as potent 
in preventing DC maturation. This is a strong support for the notion that trans-endocytosis is 
a dispensable mechanism for Treg cell-mediated suppression. Even more interesting, wild 
type Treg cells up-regulate PD-L2 on DCs upon co-culture, while Treg cells from 
Ctla4ex2fl/flFoxp3-Cre mice could not. This implies that cell-extrinsic CTLA-4 signalling can 
initiate an anti-inflammatory program in DCs that transform DCs into a suppressive 
phenotype.  
In support of this notion, a recent paper demonstrated that PKC-η associated with CTLA-4 
and was recruited to the immunological synapse of Treg cells and PKC-η-deficient Treg cells 
displayed defective suppressive ability when co-transferred with effector T cells (Kong et al. 
2014). In addition PKC-η-deficient mice developed signs of lymphoproliferative disease with 
increased numbers of memory T cells and pro-inflammatory cytokines (Fu et al. 2011). Even 
more interestingly, Sharpe and colleagues have published a paper very recently where a 
conditional knockout mouse model was generated to delete CTLA-4 in adult mice using 
tamoxifen (Paterson et al. 2015). To their surprise, the deletion of CTLA-4 in adult mice 
resulted in resistance to induced autoimmunity (mouse EAE model), which was in part due to 
a great expansion of Treg cells both in the periphery and the central nervous system. In 
addition, Treg cells lacking CTLA-4 were able to suppress homeostatic proliferation in vivo. 
An increased expression of IL-10, Lag3 and PD-1 was observed both in conventional T cells 
and Treg cells after CTLA-4 deletion. When immunizing the CTLA-4 deleted mice for EAE, 
the percentage of Treg cells was increased in the central nervous system while the level of 
CD80/CD86 on APCs was unchanged.  
Combining with the results from our study, these data suggest that: 1) CTLA-4 has cell-
intrinsic function in Treg cells where it probably regulates the homeostasis of Treg cells in 
the periphery. 2) Trans-endocytosis is dispensable for Treg cell-mediated suppression via 
CTLA-4. 3) The suppressive program on DCs initiated by Treg cells involved both CTLA-4-
dependent and independent mechanisms, and many other factors such as IL-10 and/or other 
co-inhibitory molecules may play an important role in such processes. 
There are still many unanswered questions regarding Paper III. For example, is the up-
regulation of PD-L2 dependent on the interaction between CTLA-4 exon 2 and CD80/CD86? 
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Are there any other molecules being induced in DCs after co-cultured with Treg cells? How 
much of the Treg cell mediated suppressive program induced in DCs is CTLA-4 dependent, 
and how much is CTLA-4 independent? To answer these questions, we can utilize DCs from 
CD80/CD86 knockout mice and compare them with wild type DCs co-cultured with different 
types of Treg cells. In addition, we are also planning to use RNA-sequencing to define the 
global changes in transcriptome in DCs that are suppressed by wild type and Ctla-
4ex2fl/flFoxp3-Cre Treg cells.   
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